Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis

Katherine M. Bever, Luke I. Masha, Fangui Sun, Lauren Stern, Andrea Havasi, John L. Berk, Vaishali Sanchorawala, David C. Seldin, J. Mark Sloan

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease. This retrospective study examined the frequency of venous thromboembolism in 929 patients with immunoglobulin light chain amyloidosis presenting to a single referral center, correlated risk of venous thromboembolism with clinical and laboratory factors, and examined complications of anticoagulation in this population. Sixty-five patients (7%) were documented as having at least one venous thromboembolic event. Eighty percent of these patients had events within one year prior to or following diagnosis. Lower serum albumin was associated with increased risk of VTE, with a hazard ratio of 4.30 (CI 1.60-11.55; P=0.0038) for serum albumin less than 3 g/dL compared to serum albumin greater than 4 g/dL. Severe bleeding complications were observed in 5 out of 57 patients with venous thromboembolism undergoing treatment with anticoagulation. Prospective investigation should be undertaken to better risk stratify these patients and to determine the optimal strategies for prophylaxis against and management of venous thromboembolism.

Original languageEnglish (US)
Pages (from-to)86-90
Number of pages5
Issue number1
StatePublished - 2016
Externally publishedYes

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis'. Together they form a unique fingerprint.

Cite this